journal article·2019-06

Co-delivery of antigen and dual agonists by programmed mannose-targeted cationic lipid-hybrid polymersomes for enhanced vaccination

Dunwan Zhu, Chunyan Hu, Fan Fan, Yu Qin, Chenlu Huang, Zhiming Zhang, Lu Lu, Hai Wang, Hongfan Sun, Xigang Leng, Chun Wang, Deling Kong, Linhua Zhang

Biomaterials· Volume 206
Publisher page

Abstract

Exploiting Toll-like receptor (TLR) agonists or their certain combinations can enhance the immune potency of subunit vaccine. Nevertheless, the design of co-delivery systems which can act in a synergistic and spatio-temporal way to achieve effective and durable specific immune response is still challenging. Here we fabricated mannose-functionalized lipid-hybrid polymersomes (MAN-IMO-PS) for co-delivery of ovalbumin antigen both inside the inner core and outside the lipid layer, TLR7/8 agonist imiquimod within the hydrophobic membrane, TLR4 agonist monophosphoryl lipid A in the lipid layer as programmed nanovaccine to synergistically activate immune responses for improving vaccine efficacy. After efficiently internalized by dendritic cells via mannose targeting and TLR4 ligating, MAN-IMO-PS significantly enhanced cross-presentation and cytokine production. In addition, MAN-IMO-PS showed depot effect at the injection site and enhanced migration to draining lymph nodes. Mice immunized with MAN-IMO-PS elicited greater lymphocyte activation, CD4+ and CD8+ T cell response, effector cytokines secretion, and induced Th-1 biased humoral responses. More importantly, prophylactic vaccination by MAN-IMO-PS significantly delayed tumor occurrence, suppressed tumor growth with prolonged survival, and achieved long-term immune effect. The present study demonstrates a rationally designed nanovaccine for combining antigen, different TLR agonists, and targeting moiety in a programmed manner to induce synergistic antitumor immune response.
Source: europepmc · Quality: candidate unverified · Source record ↗

Research context

OpenAlex topics: Immunotherapy and Immune Responses · Immune Response and Inflammation · RNA Interference and Gene Delivery

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (56)

Show source-provided references
1. pH-Responsive nanoparticle vaccines for dual-delivery of antigens and immunostimulatory oligonucleotides10.1021/nn305466z ↗
2. Engineering nano- and microparticles to tune immunity10.1002/adma.201200446 ↗
3. Toll-like receptor control of the adaptive immune responses10.1038/ni1112 ↗
4. Toll-dependent selection of microbial antigens for presentation by dendritic cells10.1038/nature04596 ↗
5. Multifunctional nanoparticles for cancer immunotherapy: a groundbreaking approach for reprogramming malfunctioned tumor environment10.1016/j.jconrel.2018.01.028 ↗
6. Protein direct delivery to dendritic cells using nanoparticles based on amphiphilic poly(amino acid) derivatives10.1016/j.biomaterials.2007.04.023 ↗
7. Polymersomes for drug delivery: design, formation and characterization10.1016/j.jconrel.2011.10.005 ↗
8. Folate-targeted polymersomes loaded with both paclitaxel and doxorubicin for the combination chemotherapy of hepatocellular carcinoma10.1016/j.actbio.2017.06.017 ↗
9. Polymersomes: tough vesicles made from diblock copolymers10.1126/science.284.5417.1143 ↗
10. Bubble-generating polymersomes loaded with both indocyanine green and doxorubicin for effective chemotherapy combined with photothermal therapy10.1016/j.actbio.2018.05.033 ↗
11. Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns10.1038/nri2868 ↗
12. Role of sustained antigen release from nanoparticle vaccines in shaping the T cell memory phenotype10.1016/j.biomaterials.2012.03.041 ↗
13. Immune responses to vaccines involving a combined antigen-nanoparticle mixture and nanoparticle-encapsulated antigen formulation10.1016/j.biomaterials.2014.04.022 ↗
14. Lymphatic-targeted cationic liposomes: a robust vaccine adjuvant for promoting long-term immunological memory10.1016/j.vaccine.2014.07.081 ↗
15. Lymphatic drug delivery using engineered liposomes and solid lipid nanoparticles10.1016/j.addr.2011.05.017 ↗
16. Mannose receptor-targeted vaccines10.1517/14712598.4.12.1953 ↗
17. Immature, semi-mature and fully mature dendritic cells: which signals induce tolerance or immunity?10.1016/S1471-4906(02)02281-0 ↗
18. Dual TLR agonist nanodiscs as a strong adjuvant system for vaccines and immunotherapy10.1016/j.jconrel.2018.04.041 ↗
19. Encapsulation of two different TLR ligands into liposomes confer protective immunity and prevent tumor development10.1016/j.jconrel.2017.01.004 ↗
20. Effective cancer immunotherapy in mice by polyIC-imiquimod complexes and engineered magnetic nanoparticles10.1016/j.biomaterials.2018.04.003 ↗
21. Multifunctional PLGA-based nanoparticles encapsulating simultaneously hydrophilic antigen and hydrophobic immunomodulator for mucosal immunization10.1021/mp400092y ↗
22. Cooperation of Toll-like receptor signals in innate immune defence10.1038/nri2038 ↗
23. Selected Toll-like receptor agonist combinations synergistically trigger a T helper type 1-polarizing program in dendritic cells10.1038/ni1223 ↗
24. Programming the magnitude and persistence of antibody responses with innate immunity10.1038/nature09737 ↗
25. Artificial bacterial biomimetic nanoparticles synergize pathogen-associated molecular patterns for vaccine efficacy10.1016/j.biomaterials.2016.03.039 ↗
26. Folate-modified lipid-polymer hybrid nanoparticles for targeted paclitaxel delivery
27. Programmed nanoparticles for combined immunomodulation, antigen presentation and tracking of immunotherapeutic cells10.1016/j.biomaterials.2013.10.009 ↗
28. Interbilayer-crosslinked multilamellar vesicles as synthetic vaccines for potent humoral and cellular immune responses10.1038/nmat2960 ↗
29. Liposomes containing lipid A: an effective, safe, generic adjuvant system for synthetic vaccines10.1586/erv.12.35 ↗
30. Cationic liposome-hyaluronic acid hybrid nanoparticles for intranasal vaccination with subunit antigens10.1016/j.jconrel.2015.04.010 ↗
31. pH-responsive poly(D,L-lactic-co-glycolic acid) nanoparticles with rapid antigen release behavior promote immune response10.1021/nn5066793 ↗
32. Sample size calculation in animal studies using resource equation Approach10.21315/mjms2017.24.5.11 ↗
33. Particle size and surface charge affect particle uptake by human dendritic cells in an in vitro model10.1016/j.ijpharm.2005.03.035 ↗
34. Antigen delivery by lipid-enveloped PLGA microparticle vaccines mediated by in situ vesicle shedding10.1021/bm500337r ↗
35. Dendritic cells and the control of immunity10.1038/32588 ↗
36. Cross-presentation by dendritic cells10.1038/nri3254 ↗
37. Potentiation of pH-sensitive polymer-modified liposomes with cationic lipid inclusion as antigen delivery carriers for cancer immunotherapy10.1016/j.biomaterials.2014.05.077 ↗
38. Mannose and mannose-6-phosphate receptor-targeted drug delivery systems and their application in cancer therapy
39. Receptor-mediated pinocytosis of mannose glycoconjugates by macrophages: characterization and evidence for receptor recycling10.1016/0092-8674(80)90402-X ↗
40. C-Type lectin receptor(s)-targeted nanoliposomes: an intelligent approach for effective cancer immunotherapy10.2217/nnm-2017-0088 ↗
41. Mannosylated poly(beta-amino esters) for targeted antigen presenting cell immune modulation10.1016/j.biomaterials.2014.10.037 ↗
42. Regulation of antigen transport into the cytosol for cross-presentation by ubiquitination of the mannose receptor10.1016/j.molimm.2012.10.010 ↗
43. Requirement of mature dendritic cells for efficient activation of influenza A-specific memory CD8+ T cells10.4049/jimmunol.165.3.1182 ↗
44. IFN-alpha skews monocyte differentiation into Toll-like receptor 7-expressing dendritic cells with potent functional activities10.4049/jimmunol.171.7.3385 ↗
45. Tumour necrosis factor-alpha (TNF-alpha) transgene-expressing dendritic cells (DCs) undergo augmented cellular maturation and induce more robust T-cell activation and anti-tumour immunity than DCs generated in recombinant TNF-alpha10.1046/j.1365-2567.2003.01489.x ↗
46. A brief history of T cell help to B cells10.1038/nri3803 ↗
47. Effector and memory T-cell differentiation: implications for vaccine development10.1038/nri778 ↗
48. Dendritic-cell trafficking to lymph nodes through lymphatic vessels10.1038/nri1670 ↗
49. Regulation of antibody isotype secretion by subsets of antigen-specific helper T cells10.1038/334255a0 ↗
50. Interferons, immunity and cancer immunoediting10.1038/nri1961 ↗
51. Cytotoxic cells kill intracellular bacteria through granulysin-mediated delivery of granzymes10.1016/j.cell.2014.03.062 ↗
52. Immune system targeting by biodegradable nanoparticles for cancer vaccines10.1016/j.jconrel.2013.03.010 ↗
53. Multiple roles for CD4+ T cells in anti-tumor immune responses10.1111/j.1600-065X.2008.00616.x ↗
54. Central memory and effector memory T cell subsets: function, generation, and maintenance10.1146/annurev.immunol.22.012703.104702 ↗
55. Novel vaccine delivery system induces robust humoral and cellular immune responses based on multiple mechanisms10.1002/adhm.201300335 ↗
56. Introduction of soluble protein into the class I pathway of antigen processing and presentation10.1016/S0092-8674(88)91043-4 ↗